Anticoagulation: Warfarin & DOACs

Anticoagulation: Warfarin & DOACs

Master anticoagulation therapy with free flashcards and spaced repetition practice. This lesson covers warfarin management, INR monitoring, direct oral anticoagulants (DOACs), reversal agents, and drug interactions—essential concepts for NAPLEX success and safe clinical practice.

Welcome to Anticoagulation Therapy 💊

Anticoagulation represents one of the most critical yet challenging areas of pharmacotherapy. Every year, millions of patients rely on anticoagulants to prevent devastating thromboembolic events, yet these same medications consistently rank among the highest-risk drugs for adverse events. As a pharmacist, you'll serve as a vital checkpoint for ensuring appropriate selection, dosing, monitoring, and patient education.

This lesson will equip you with high-yield knowledge about warfarin's complex pharmacology and the newer direct oral anticoagulants that have transformed anticoagulation management. You'll learn when to use each agent, how to monitor therapy, what to do when things go wrong, and how to navigate the countless drug interactions that make anticoagulation so challenging.

---

Core Concept 1: Warfarin Pharmacology & Mechanism 🎯

Warfarin is a vitamin K antagonist that inhibits the vitamin K epoxide reductase complex (VKORC1), preventing the reduction of vitamin K epoxide back to its active form. This disrupts the gamma-carboxylation of clotting factors II, VII, IX, and X, as well as the anticoagulant proteins C and S.

The Vitamin K Cycle

┌────────────────────────────────────────────┐
│        VITAMIN K CYCLE                     │
├────────────────────────────────────────────┤
│                                            │
│  Vitamin K (reduced) ──→ Vitamin K epoxide │
│         ↑                       │          │
│         │        WARFARIN        │          │
│         │        BLOCKS ⚠️       │          │
│         │                       ↓          │
│    VKORC1 ←────────────────────┘          │
│   (enzyme)                                 │
│                                            │
│  Reduced Vitamin K needed for:            │
│  ✓ Factor II (prothrombin)                │
│  ✓ Factor VII                             │
│  ✓ Factor IX                              │
│  ✓ Factor X                               │
│  ✓ Protein C & S (anticoagulant)          │
└────────────────────────────────────────────┘

Key Warfarin Characteristics

Property	Detail
Absorption	Rapid, complete oral absorption
Onset	36-72 hours (requires depletion of existing factors)
Peak Effect	5-7 days
Half-life	40 hours (20-60 hour range)
Metabolism	CYP2C9 (major), CYP1A2, CYP3A4
Monitoring	INR (International Normalized Ratio)
Protein Binding	99% (albumin)

Why the Delayed Onset? ⏰

This is a high-yield NAPLEX concept: Warfarin doesn't immediately anticoagulate because it only prevents the synthesis of new clotting factors. Existing functional factors must be depleted first.

Factor Half-Lives (shortest to longest):

• Factor VII: 6 hours (depletes first → INR rises quickly)
• Factor IX: 24 hours
• Factor X: 48 hours
• Factor II: 60 hours (depletes last → full anticoagulation delayed)

💡 Clinical Pearl: The initial INR rise (24-48 hours) reflects Factor VII depletion but doesn't indicate full anticoagulation. You must wait until Factor II depletes (5-7 days) for true therapeutic effect.

The Protein C Paradox ⚠️

Protein C (anticoagulant protein) has a half-life of only 8 hours. When warfarin is initiated, Protein C depletes before the procoagulant factors II and X, creating a temporary hypercoagulable state in the first 24-48 hours.

Clinical Consequence: Risk of warfarin-induced skin necrosis, especially in patients with Protein C or S deficiency.

Prevention Strategy: Bridge with heparin or LMWH during warfarin initiation for at least 5 days AND until INR ≥2 for at least 24 hours.

---

Core Concept 2: INR Monitoring & Target Ranges 📊

INR (International Normalized Ratio) standardizes PT (prothrombin time) measurements across different laboratories and thromboplastin reagents.

Formula: INR = (Patient PT / Mean Normal PT)^ISI

• ISI = International Sensitivity Index of the thromboplastin reagent

Target INR Ranges by Indication

Indication	Target INR	Duration
DVT/PE (provoked)	2-3	3 months
DVT/PE (unprovoked)	2-3	≥3 months (often indefinite)
Atrial fibrillation	2-3	Indefinite
Mechanical heart valve (bileaflet aortic)	2-3	Lifelong
Mechanical heart valve (mitral position)	2.5-3.5	Lifelong
Mechanical heart valve (older models)	2.5-3.5	Lifelong
Recurrent VTE on warfarin	2.5-3.5	Indefinite
Antiphospholipid syndrome	2-3	Indefinite

INR Monitoring Schedule 📅

Initiation Phase:

• Baseline INR before starting
• INR after 2-3 doses
• INR every 2-3 days until stable
• Daily INR if hospitalized

Maintenance Phase:

• Weekly INR until stable for 2 consecutive weeks
• Every 2 weeks for 1-2 months
• Every 4 weeks once stable (can extend to 12 weeks in highly stable patients)

After Dose Adjustment:

• INR in 5-7 days (full effect)
• More frequent if large adjustment

💡 NAPLEX Tip: Remember that a dose change today won't fully affect INR for 5-7 days due to warfarin's long half-life and factor depletion kinetics.

Dosing Adjustments: The 10-20% Rule 📐

INR Result	Action
<1.5	Increase weekly dose by 10-20%
1.5-1.9	Increase weekly dose by 5-10%
2.0-3.0	No change (maintain current dose)
3.1-4.0	Decrease weekly dose by 5-10%
4.1-5.0	Hold 0-1 dose; decrease weekly by 10-15%
5.1-9.0 (no bleeding)	Hold 1-2 doses; decrease weekly by 10-20%
>9.0 (no bleeding)	Hold warfarin; vitamin K 2.5-5 mg PO
Any INR with major bleeding	Hold warfarin; 4-factor PCC + vitamin K 10 mg IV

🧠 Memory Device - "The WARFARIN Mnemonic":

• Weekly dose adjustments (think total weekly, not daily)
• Avoid big jumps (10-20% max)
• Recheck in 5-7 days after change
• Factor depletion takes time
• Albumin binding matters (drug interactions)
• Reversal with vitamin K (slow) or PCC (fast)
• INR targets: 2-3 most common, 2.5-3.5 for mechanical mitral
• No loading dose (causes Protein C paradox)

---

Core Concept 3: Warfarin Drug Interactions 💥

Warfarin has hundreds of clinically significant drug interactions. Understanding the mechanisms helps predict which drugs will interact.

Interaction Mechanisms

┌────────────────────────────────────────────────┐
│   WARFARIN INTERACTION MECHANISMS              │
├────────────────────────────────────────────────┤
│                                                │
│  1️⃣ CYP2C9 INHIBITION → ↑ INR                │
│     (blocks warfarin metabolism)               │
│                                                │
│  2️⃣ CYP2C9 INDUCTION → ↓ INR                 │
│     (increases warfarin clearance)             │
│                                                │
│  3️⃣ VITAMIN K SOURCES → ↓ INR                │
│     (dietary vitamin K competes)               │
│                                                │
│  4️⃣ ANTIPLATELET EFFECTS → ↑ Bleeding        │
│     (INR unchanged, bleeding risk ↑)           │
│                                                │
│  5️⃣ PROTEIN BINDING DISPLACEMENT → ↑ INR     │
│     (increases free warfarin transiently)      │
│                                                │
│  6️⃣ VITAMIN K PRODUCTION → ↓ INR             │
│     (antibiotics kill gut flora)               │
└────────────────────────────────────────────────┘

High-Yield Interacting Drugs

Drugs That INCREASE INR (↑ bleeding risk):

Drug/Class	Mechanism	Management
Amiodarone	CYP2C9 inhibition (potent)	Decrease warfarin dose 30-50%
Metronidazole	CYP2C9 inhibition	Monitor closely; may need 25-30% reduction
Fluconazole	CYP2C9 inhibition (dose-dependent)	Decrease dose 25-50%
Trimethoprim/sulfamethoxazole	CYP2C9 inhibition	Monitor INR in 3-5 days
Acetaminophen	Unknown (dose >2g/day for >1 week)	Monitor if chronic high-dose use
NSAIDs	Antiplatelet + GI risk (INR may not change!)	Avoid if possible; use gastroprotection
SSRIs	Antiplatelet effects	Monitor for bleeding

Drugs That DECREASE INR (↓ efficacy):

Drug/Class	Mechanism	Management
Rifampin	CYP2C9 induction (very potent)	May need to double warfarin dose
Carbamazepine	CYP2C9 induction	Increase dose 25-50%
Phenytoin	CYP2C9 induction (complex, biphasic)	Frequent monitoring
St. John's Wort	CYP induction	AVOID - unpredictable
Vitamin K supplements	Competitive antagonism	Consistent intake if used
Green leafy vegetables	Vitamin K content	Consistent diet (not avoidance!)

Antibiotic Effects on INR 💊

Antibiotics cause some of the most common warfarin interactions in practice:

1. Direct CYP2C9 inhibition: Metronidazole, trimethoprim/sulfamethoxazole, fluconazole
2. Gut flora disruption: Reduced vitamin K2 production (minor effect, controversial)
3. Acute illness: Decreased vitamin K intake, altered liver function

Clinical Approach: Check INR 3-5 days after starting any antibiotic in a warfarin patient.

Dietary Vitamin K: The Consistency Rule 🥬

High Vitamin K Foods (>200 mcg per serving):

• Kale, spinach, collard greens, turnip greens
• Broccoli, Brussels sprouts
• Green tea (large amounts)
• Natto (fermented soybeans)

💡 Key Patient Education: "Eat your greens, just eat them consistently!"

Don't avoid vitamin K foods—sudden dietary changes (starting or stopping) cause INR instability. A patient who eats salad daily should continue; one who never eats greens shouldn't suddenly start.

---

Core Concept 4: Direct Oral Anticoagulants (DOACs) 🎯

DOACs have largely replaced warfarin for non-valvular atrial fibrillation and VTE due to their predictable pharmacokinetics, lack of monitoring, and fewer drug interactions.

The DOAC Family

Drug	Target	Half-life	Renal Elimination	Dosing Frequency
Dabigatran	Direct thrombin (IIa)	12-17 hours	80%	BID
Rivaroxaban	Factor Xa	5-9 hours	33%	Daily (BID for VTE treatment first 21 days)
Apixaban	Factor Xa	12 hours	27%	BID
Edoxaban	Factor Xa	10-14 hours	50%	Daily

DOAC Mechanism Comparison

        COAGULATION CASCADE

    Intrinsic    Extrinsic
    Pathway      Pathway
         \          /
          \        /
           ↓      ↓
         Factor X
              │
         Factor Xa ←──── 🔴 Rivaroxaban
              │          🔴 Apixaban  
              │          🔴 Edoxaban
              ↓
         Prothrombin (Factor II)
              │
         Thrombin (Factor IIa) ←──── 🔵 Dabigatran
              │
              ↓
         Fibrinogen → Fibrin
              │
              ↓
         🩸 Clot Formation

Atrial Fibrillation Dosing (Stroke Prevention) 🫀

Dabigatran:

• Standard: 150 mg BID
• Reduced: 75 mg BID if CrCl 15-30 mL/min
• Avoid if CrCl <15 mL/min or on dialysis

Rivaroxaban:

• Standard: 20 mg daily with evening meal
• Reduced: 15 mg daily if CrCl 15-50 mL/min
• Avoid if CrCl <15 mL/min

Apixaban:

• Standard: 5 mg BID
• Reduced: 2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, SCr ≥1.5 mg/dL
• Can use if CrCl 15-29 mL/min (use reduced dose)

Edoxaban:

• Standard: 60 mg daily
• Reduced: 30 mg daily if CrCl 15-50 mL/min, weight ≤60 kg, or with P-gp inhibitors
• AVOID if CrCl >95 mL/min (increased stroke risk in trials)

⚠️ NAPLEX High-Yield: Apixaban dose reduction requires TWO or more criteria (not just one). Edoxaban is contraindicated with CrCl >95 mL/min.

VTE Treatment Dosing 🩸

All DOACs approved for VTE, but dosing differs from AFib:

Dabigatran:

• Requires 5-10 day parenteral anticoagulant lead-in (heparin/LMWH)
• Then 150 mg BID

Rivaroxaban:

• 15 mg BID × 21 days (with food)
• Then 20 mg daily (with food)
• No parenteral lead-in needed

Apixaban:

• 10 mg BID × 7 days
• Then 5 mg BID
• No parenteral lead-in needed

Edoxaban:

• Requires 5-10 day parenteral anticoagulant lead-in
• Then 60 mg daily (30 mg if dose reduction criteria met)

💡 Memory Device - DOAC VTE Lead-in: "DAbigatran and Edoxaban need DAys (and Enoxaparin) first!" Rivaroxaban and Apixaban can start immediately with higher initial doses.

DOAC Drug Interactions 🔄

DOACs have fewer interactions than warfarin but still clinically important ones:

P-glycoprotein (P-gp) Interactions:

All DOACs are P-gp substrates. Strong P-gp inhibitors/inducers affect levels:

Interacting Drug	Effect	Management
Rifampin (inducer)	↓ DOAC levels	Avoid combination
Carbamazepine (inducer)	↓ DOAC levels	Avoid combination
Phenytoin (inducer)	↓ DOAC levels	Avoid combination
Ketoconazole (inhibitor)	↑ DOAC levels	Reduce DOAC dose or avoid
Dronedarone (inhibitor)	↑ DOAC levels	Reduce dabigatran to 75 mg BID

CYP3A4 Interactions (Xa inhibitors only):

Rivaroxaban and apixaban are metabolized by CYP3A4:

Dual P-gp + CYP3A4 inhibitors (highest risk):

• Ketoconazole, itraconazole, ritonavir, clarithromycin
• Action: Avoid combination or reduce dose significantly

DOAC vs. Warfarin: When to Use Which? 🤔

Prefer DOACs for:

• Non-valvular atrial fibrillation
• VTE treatment in most patients
• Patients with difficulty monitoring INR
• Patients with multiple drug interactions on warfarin
• Patients with unstable INRs

Prefer Warfarin for:

• Mechanical heart valves (DOACs contraindicated)
• Moderate-severe mitral stenosis
• CrCl <15 mL/min (except apixaban possibly)
• Antiphospholipid syndrome (dabigatran inferior)
• Extremes of body weight (>120 kg or <50 kg - limited data)
• Medication cost concerns (warfarin much cheaper)

⚠️ Black Box Warning: DOACs showed increased thromboembolic events in patients with mechanical heart valves. This is an absolute contraindication.

---

Core Concept 5: Reversal Agents & Bleeding Management 🚨

Knowing how to reverse anticoagulation in life-threatening bleeding is critical for NAPLEX and clinical practice.

Warfarin Reversal

Scenario	Treatment	Onset	Duration
INR 5-9, no bleeding	Hold 1-2 doses; resume at lower dose	24-48 hrs	-
INR >9, no bleeding	Vitamin K 2.5-5 mg PO	24 hrs	Days
Major bleeding	4-factor PCC 25-50 units/kg IV + Vitamin K 10 mg IV	10-30 min	6-12 hrs (PCC)
Urgent surgery (8-12 hrs)	Vitamin K 2.5-5 mg PO/IV	4-6 hrs IV, 12-24 hrs PO	Days
Emergency surgery (now)	4-factor PCC + Vitamin K 10 mg IV	10-30 min	Variable

4-Factor Prothrombin Complex Concentrate (PCC):

• Contains factors II, VII, IX, X (all vitamin K-dependent factors)
• Preferred over FFP (faster, smaller volume, no blood typing needed)
• Brand names: KCentra, Bebulin, Profilnine
• Dosing based on baseline INR and weight

Fresh Frozen Plasma (FFP):

• Second-line (when PCC unavailable)
• Requires 15-30 mL/kg (large volume)
• Slower onset, risk of volume overload and transfusion reactions

💡 NAPLEX Pearl: Always give vitamin K with PCC because PCC only lasts 6-12 hours while warfarin effect persists for days.

DOAC Reversal

Idarucizumab (Praxbind) - Dabigatran-Specific:

• Monoclonal antibody fragment that binds dabigatran
• Dose: 5 g IV (two 2.5 g vials)
• Onset: Minutes
• Reverses dabigatran within 15 minutes
• Indicated for life-threatening bleeding or urgent surgery

Andexanet alfa (Andexxa) - Xa Inhibitor Reversal:

• Recombinant Factor Xa decoy protein
• Binds rivaroxaban, apixaban, edoxaban
• Dosing: Low-dose (400 mg bolus + 480 mg infusion) or high-dose (800 mg bolus + 960 mg infusion)
• Onset: Minutes
• Duration: ~2 hours (anti-Xa activity may return)

4-Factor PCC (off-label for DOACs):

• May be used if specific reversal agents unavailable
• Evidence mixed; theoretically replenishes clotting factors
• Dose: 25-50 units/kg IV

┌─────────────────────────────────────────────┐
│      REVERSAL AGENT DECISION TREE           │
├─────────────────────────────────────────────┤
│                                             │
│  Life-threatening bleeding or urgent        │
│  surgery in anticoagulated patient          │
│                │                            │
│                ▼                            │
│         Which anticoagulant?                │
│                │                            │
│      ┌─────────┴──────────┐                │
│      ▼                    ▼                │
│   WARFARIN            DOAC                 │
│      │                    │                │
│      │           ┌────────┴────────┐       │
│      │           ▼                 ▼       │
│      │      Dabigatran        Xa inhibitor │
│      │           │              (R/A/E)    │
│      ▼           ▼                 ▼       │
│  PCC 25-50      Idarucizumab    Andexanet  │
│  units/kg       5 g IV          (dose by   │
│  +                              protocol)  │
│  Vitamin K                                  │
│  10 mg IV                                   │
│                                             │
│  If specific reversal unavailable:          │
│  → 4-factor PCC 50 units/kg                │
└─────────────────────────────────────────────┘

⚠️ Important Limitation: Andexanet alfa is very expensive ($25,000-50,000 per dose) and may not be stocked at all hospitals. Have a backup plan with PCC.

---

Examples: Applying Anticoagulation Knowledge 📚

Example 1: Warfarin Initiation & Bridging

Case: 68-year-old male with new-onset atrial fibrillation (CHA₂DS₂-VASc score = 4). No prior VTE. CrCl 65 mL/min. Admitted to hospital.

Question: What is the appropriate anticoagulation strategy?

Answer:

1. CHA₂DS₂-VASc = 4 → High stroke risk → Anticoagulation indicated
2. Options: DOAC preferred over warfarin for non-valvular AFib (easier management, similar/better efficacy)
3. If using DOAC: Start immediately (e.g., apixaban 5 mg BID)
4. If using warfarin (e.g., cost concern):
   • Start warfarin 5 mg daily (typical initial dose)
   • Bridge with LMWH (e.g., enoxaparin 1 mg/kg SC Q12H) or UFH
   • Continue bridge for minimum 5 days AND until INR 2-3 × 24 hours
   • Check INR after 2-3 doses, then every 2-3 days until stable

Rationale: Bridging prevents thromboembolism during the 5-7 days before warfarin achieves therapeutic anticoagulation. The INR may reach 2-3 in 3-4 days, but you must continue bridging for full 5 days to ensure Factor II depletion.

Example 2: INR Supratherapeutic Management

Case: 72-year-old woman on warfarin for AFib. Target INR 2-3. Called pharmacy with new INR result of 6.8. No signs of bleeding. Started trimethoprim/sulfamethoxazole 3 days ago for UTI.

Question: What is your recommendation?

Answer:

Immediate Actions:

1. Hold warfarin for 1-2 doses
2. Vitamin K 2.5 mg PO (INR 5-9 with some bleeding risk factors: age >75, taking antibiotic)
3. Recheck INR in 24-48 hours
4. Resume warfarin at 10-20% lower weekly dose when INR <3

Address Drug Interaction:

• Trimethoprim/sulfamethoxazole inhibits CYP2C9 → increased warfarin levels
• Will need reduced warfarin dose while on antibiotic and for ~1 week after completion
• Consider more frequent INR monitoring (every 3-5 days) during antibiotic course

Patient Education:

• Avoid activities with high bleeding risk
• Watch for bleeding signs: unusual bruising, black stools, blood in urine, severe headache
• Call immediately if bleeding occurs

Rationale: INR 6.8 without bleeding is managed conservatively with holding doses and low-dose oral vitamin K. IV vitamin K works faster but may cause warfarin resistance for days. The antibiotic interaction is predictable and requires dose adjustment.

Example 3: Transitioning from Warfarin to DOAC

Case: 55-year-old man with AFib on warfarin (INR 2-3) wants to switch to apixaban due to difficulty with INR monitoring (works offshore on oil rig for weeks at a time). Current INR = 2.4. CrCl 85 mL/min. Weight 88 kg.

Question: How do you transition?

Answer:

Apixaban Dose Selection:

• Standard dose 5 mg BID (doesn't meet dose reduction criteria: age <80, weight >60 kg, SCr <1.5)

Transition Protocol:

1. Stop warfarin
2. Start apixaban when INR <2.0
3. Check INR in 2-3 days to confirm <2.0
4. If INR still ≥2.0, wait another day and recheck

Timeline:

• Day 1: Stop warfarin (INR = 2.4)
• Day 3-4: Check INR → likely 1.5-1.9
• If INR <2.0: Start apixaban 5 mg BID
• If INR ≥2.0: Wait and recheck daily

Patient Education:

• Apixaban must be taken twice daily (more important than warfarin since no monitoring)
• Take with or without food
• Don't stop without consulting provider (stroke risk returns immediately)
• Still avoid NSAIDs if possible (bleeding risk)

Rationale: Starting DOAC while INR ≥2.0 increases bleeding risk due to overlapping anticoagulation. Wait until INR <2.0 ensures warfarin effect is waning. Unlike warfarin-to-heparin transition, no bridging needed for DOAC since onset is rapid (2-4 hours).

Example 4: DOAC Selection in Renal Impairment

Case: 82-year-old woman with AFib needs anticoagulation. CrCl = 28 mL/min, weight = 54 kg, SCr = 1.8 mg/dL. No mechanical valve. CHA₂DS₂-VASc = 6.

Question: Which anticoagulant and dose?

Answer:

Analysis by DOAC:

1. Dabigatran:

   • CrCl 15-30: Use 75 mg BID
   • CrCl 28: ✅ Can use 75 mg BID

2. Rivaroxaban:

   • CrCl 15-50: Use 15 mg daily (with food)
   • CrCl 28: ✅ Can use 15 mg daily

3. Apixaban:

   • Dose reduction if ≥2 of: age ≥80, weight ≤60 kg, SCr ≥1.5
   • This patient: Age 82 ✓, weight 54 kg ✓, SCr 1.8 ✓ → All three criteria!
   • Use 2.5 mg BID ✅
   • Best choice (can use down to CrCl 15)

4. Edoxaban:

   • CrCl 15-50: Use 30 mg daily
   • Also reduce if weight ≤60 kg
   • CrCl 28 + weight 54: ✅ Can use 30 mg daily

Recommendation: Apixaban 2.5 mg BID

Rationale: All DOACs can be used in this patient with dose reductions, but apixaban has the most data in severe renal impairment and can be used down to CrCl 15 mL/min. It also has the lowest renal elimination (27%). Dabigatran with 80% renal elimination would be last choice despite being usable at this CrCl.

---

Common Mistakes to Avoid ⚠️

Mistake 1: Starting Warfarin Without Bridging in High VTE Risk

Error: Starting warfarin alone in patient with acute DVT/PE Why it's wrong: Protein C depletion (first 24-48 hours) creates transient hypercoagulable state before achieving anticoagulation Correct approach: Always bridge with LMWH/heparin for ≥5 days AND until INR therapeutic × 24 hours

Mistake 2: Switching to DOAC While INR Still Therapeutic

Error: Starting apixaban when INR = 2.5 Why it's wrong: Excessive anticoagulation from overlap increases bleeding risk significantly Correct approach: Wait until INR <2.0 before initiating DOAC

Mistake 3: Using Single Dose Reduction Criterion for Apixaban

Error: Reducing apixaban to 2.5 mg BID because patient is 82 years old (only one criterion) Why it's wrong: Requires ≥2 of 3 criteria (age ≥80, weight ≤60 kg, SCr ≥1.5) Correct approach: Use standard 5 mg BID unless patient meets TWO or more criteria

Mistake 4: Forgetting Rivaroxaban Food Requirement

Error: Instructing patient to take rivaroxaban 20 mg "once daily" without food specification Why it's wrong: Absorption reduced by 30-50% without food, decreasing efficacy Correct approach: "Take 20 mg once daily WITH FOOD" (especially evening meal for adherence)

Mistake 5: Using DOACs in Mechanical Heart Valves

Error: Switching patient with mechanical mitral valve to rivaroxaban for convenience Why it's wrong: RE-ALIGN trial showed increased thrombotic events with dabigatran vs warfarin; DOACs contraindicated Correct approach: Mechanical valves = warfarin only (target INR 2.5-3.5 for mitral position)

Mistake 6: Immediate INR Recheck After Dose Change

Error: Changing warfarin dose and rechecking INR the next day Why it's wrong: Full effect of dose change takes 5-7 days due to long half-life and factor kinetics Correct approach: Recheck INR 5-7 days after dose adjustment

Mistake 7: Vitamin K Overuse for Minor INR Elevation

Error: Giving vitamin K for INR 3.8 with no bleeding Why it's wrong: Makes patient warfarin-resistant for days; difficult to re-achieve therapeutic INR Correct approach: Hold 0-1 dose and reduce weekly dose 5-10%; reserve vitamin K for INR >9 without bleeding or any bleeding scenario

Mistake 8: Not Adjusting for Amiodarone Interaction

Error: Starting amiodarone in warfarin patient without warfarin dose reduction Why it's wrong: Amiodarone is potent CYP2C9 inhibitor; INR will rise significantly, causing bleeding Correct approach: Reduce warfarin dose 30-50% when starting amiodarone; monitor INR weekly × 4 weeks

Mistake 9: Overlooking Edoxaban CrCl >95 Contraindication

Error: Prescribing edoxaban 60 mg daily to healthy 45-year-old with AFib (CrCl 110) Why it's wrong: ENGAGE-AF trial showed increased stroke risk with CrCl >95 mL/min (rapid renal clearance) Correct approach: Choose different DOAC for CrCl >95; reserve edoxaban for CrCl 15-95

Mistake 10: Telling Warfarin Patients to Avoid All Green Vegetables

Error: "Don't eat any salad or broccoli while on warfarin" Why it's wrong: Unnecessary restriction; consistency matters, not avoidance Correct approach: "Eat your normal diet consistently. If you eat salad twice a week, continue that. Don't suddenly start eating kale every day or completely stop greens."

---

Key Takeaways 🎯

Warfarin Mastery Points

1. ✅ Warfarin blocks VKORC1, preventing vitamin K recycling
2. ✅ Factor VII depletes first (6h half-life) but Factor II (60h) determines full anticoagulation
3. ✅ Always bridge with heparin/LMWH for ≥5 days AND until INR therapeutic × 24 hours
4. ✅ Target INR 2-3 for most indications; 2.5-3.5 for mechanical mitral valves
5. ✅ Full effect of dose change takes 5-7 days
6. ✅ Amiodarone, metronidazole, fluconazole, trimethoprim/sulfamethoxazole = major INR increasers
7. ✅ Rifampin, carbamazepine = major INR decreasers
8. ✅ Emergency reversal: 4-factor PCC + vitamin K 10 mg IV
9. ✅ Consistent vitamin K intake (not avoidance) is key
10. ✅ Check INR 3-5 days after starting any antibiotic

DOAC Mastery Points

1. ✅ Dabigatran = direct thrombin inhibitor; others target Factor Xa
2. ✅ Apixaban dose reduction needs ≥2 criteria (age ≥80, weight ≤60 kg, SCr ≥1.5)
3. ✅ Rivaroxaban must be taken with food (≥15 mg doses)
4. ✅ Edoxaban contraindicated if CrCl >95 mL/min
5. ✅ Dabigatran and edoxaban require parenteral lead-in for VTE treatment
6. ✅ Rivaroxaban and apixaban can start immediately for VTE (higher initial doses)
7. ✅ All DOACs contraindicated in mechanical heart valves
8. ✅ Idarucizumab reverses dabigatran; andexanet alfa reverses Xa inhibitors
9. ✅ Strong P-gp inducers (rifampin, carbamazepine, phenytoin) = avoid with DOACs
10. ✅ Transition warfarin→DOAC when INR <2.0

Bleeding Management Priorities

1. ✅ Stop anticoagulant immediately
2. ✅ Provide mechanical compression if accessible bleeding
3. ✅ Administer specific reversal agent if life-threatening
4. ✅ Transfuse PRBCs if Hgb <7 g/dL (or <8 in cardiac patients)
5. ✅ Monitor coagulation parameters post-reversal
6. ✅ Restart anticoagulation when bleeding controlled (individualize timing based on thromboembolic vs. bleeding risk)

---

Quick Reference Card 📋

---

📚 Further Study Resources

1. American College of Chest Physicians (CHEST) Antithrombotic Guidelines
   https://www.chestnet.org/Guidelines-and-Resources/Guidelines-and-Consensus-Statements/Antithrombotic-Therapy

2. ACC/AHA Atrial Fibrillation Guidelines
   https://www.acc.org/guidelines/about-guidelines-and-clinical-documents/guidelines-and-documents-listing/atrial-fibrillation

3. Pharmacist's Letter - Anticoagulation Comparison Table
   https://pharmacistsletter.therapeuticresearch.com

---

💡 Final NAPLEX Strategy: Anticoagulation questions focus heavily on dosing in renal impairment, drug interactions, reversal agents, and contraindications. Memorize apixaban's dose reduction criteria (≥2 of 3), edoxaban's CrCl >95 contraindication, and warfarin bridging duration (5 days minimum). Practice calculations for warfarin dose adjustments and know the reversal agents cold—these are high-yield, frequently tested topics!